efficacy claim for PROVENGE.
-- Implemented a committed equity financing facility under which the
Company may sell up to $130 million of its registered common stock to
Azimuth Opportunity, Ltd. over an 18-month period. Dendreon is not
obligated to utilize any of the $130 million facility and remains free
to enter into and consummate other equity and debt financing
-- Results from a Phase 1 study of NEUVENGE, an investigational active
cellular immunotherapy, were published in the August 20th issue of the
Journal of Clinical Oncology. The article highlighted the safety
profile, immune response and clinical activity of NEUVENGE in women
with HER2/neu-positive breast cancer who have failed standard therapy.
"We achieved an important milestone this quarter by completing enrollment of our Phase 3 IMPACT trial of PROVENGE, a therapy we believe has the potential to positively impact the lives of many prostate cancer patients who currently have few treatment options," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are grateful to the patients, clinical investigators and nurses who participated in this study. In addition, we would like to thank our vendors and suppliers, in particular the American Red Cross, Progenitor Cell Therapy and the Mayo Clinic, each of which provided high-quality, consistently excellent cell processing and service throughout the trial. We look forward to receiving interim results from this important study next year."
Conference Call Information
Dendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m.
ET. To access the live call, dial 1-877-397-0235 (domestic) or +1
719-325-4876 (international). The call will also be audio webcast and will
be available from the Company's website at http://www
|SOURCE Dendreon Corporation|
Copyright©2007 PR Newswire.
All rights reserved